	US 12,077,513 B2
	Process route of compound of formula (IV), crystal form and preparation method therefor
Zhi Luo, Shanghai (CN); Xiaolin Li, Shanghai (CN); Yaxun Yang, Shanghai (CN); Lele Yang, Shanghai (CN); Peng Li, Shanghai (CN); Haiying He, Shanghai (CN); Jian Li, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to SHANDONG DANHONG PHARMACEUTICAL CO., LTD., Shandong (CN)
Appl. No. 17/311,431
Filed by SHANDONG DANHONG PHARMACEUTICAL CO., LTD., Shandong (CN)
PCT Filed Dec. 20, 2019, PCT No. PCT/CN2019/127155 § 371(c)(1), (2) Date Jun. 7, 2021, PCT Pub. No. WO2020/125776, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 201811565301.3 (CN), filed on Dec. 20, 2018.
Prior Publication US 2022/0024880 A1, Jan. 27, 2022
Int. Cl. C07D 249/08 (2006.01)

CPC C07D 249/08 (2013.01) [C07B 2200/13 (2013.01)]

16 Claims

1. A crystal form A of a compound of formula (IV), wherein the X-ray powder diffraction (XRPD) pattern thereof has characteristic diffraction peaks at the following 2θ angles: 9.05±0.2°, 12.34±0.2°, and 22.52±0.2°,